BioMarin Pharmaceutical (NASDAQ:BMRN) held its 2026 annual meeting of stockholders virtually, with shareholders approving all four proposals presented during the meeting, according to the company’s meeting transcript.
Alexander Hardy, BioMarin’s president and chief executive officer, presided over the meeting. Eric Fleekop, BioMarin’s vice president and deputy general counsel, acted as secretary. Hardy said the company’s board annually considers the appropriate format for the annual meeting and chose to hold the 2026 meeting virtually.
Quorum Established
Christina Perino, representing the Carideo Group and serving as inspector of election, reported that 175,813,292 shares of BioMarin common stock were present virtually or represented by proxy. That represented approximately 90.96% of the shares issued, outstanding and entitled to vote at the meeting.
Based on that attendance, Hardy declared that a quorum was present and that the meeting was duly convened to conduct business.
Four Proposals Approved
Stockholders voted on four proposals outlined in BioMarin’s proxy statement. No questions were submitted online regarding the proposals before voting concluded, according to Hardy.
- Election of directors: Stockholders elected 10 nominees to BioMarin’s board of directors.
- Auditor ratification: Stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the year ending Dec. 31, 2026.
- Executive compensation: Stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers as disclosed in the company’s proxy statement.
- Equity incentive plan: Stockholders approved an amendment to BioMarin’s 2017 Equity Incentive Plan, as amended.
The director nominees presented for election were Alexander Hardy, Elizabeth Anderson, Barbara Bodem, Ian Clark, Athena Countouriotis, Willard Deer, Mark Enyedy, Maykin Ho, Robert J. Hombach and Timothy Walbert. Perino reported that a majority of shares cast and entitled to vote were voted in favor of each director nominee.
Final Results to Be Filed With SEC
Following Perino’s report, Hardy declared that all director nominees had been elected and that the remaining three proposals had been approved. He said a full tally of the final voting results would be published in a Form 8-K to be filed with the Securities and Exchange Commission within four business days of the meeting.
After adjourning the formal portion of the meeting, Hardy said stockholders could submit questions on general matters through the online platform in accordance with the meeting’s rules of conduct and procedures. He noted that Jason Trimborne of KPMG LLP, BioMarin’s independent auditor, was also available on the call to respond to appropriate questions. No questions were submitted online, and the meeting concluded.
About BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
